Signal · Supply Chain & Logistics
Celltrion expands Japan push with SteQeyma IV launch
What the source reported
Source-reportedCelltrion said Friday it has launched the intravenous formulation of SteQeyma for autoimmune diseases in Japan. Celltrion launched the IV formulation about four months after receiving approval from Japan’s Ministry of Health, Labour and Welfare in April. In addition to its existing indications for psoriasis and psoriatic arthritis, the product now also covers Crohn’s disease, significantly expanding its treatment scope. Celltrion’s Japanese subsidiary plans to leverage its sales expertise built
- Publication
- The Korea Herald - Business · Business News
- Published
- 21st August 2026
- Original report
- koreaherald.com
ProcIntel stores what the source published in its feed — a headline, a summary and a link. It does not store or reproduce the full article.
What ProcIntel recorded
ProcIntel-derived- Category
- Supply Chain & Logistics
- Geography
- South Korea
- Organisations
- None identified
- Collected
- 21st August 2026 · 08:34
Initial assessment ProcIntel's automatic, provisional read of this individual Signal -- Initial Significance and Initial Confidence, computed deterministically before any Event extraction or human review.
A provisional, automatically computed reading of this individual Signal, before Event extraction or human review. Not a final rating.
Initial Significance Low (15.0/100). Strongest contributor: Procurement Impact (6.0/30 points). Limiting factor: Impact-Scale Specificity (0.0/10 points). Initial Confidence Very Low (12.5/100, data sufficiency: Insufficient). Strongest contributor: Source Authority (12.0/40 points). Limiting factor: Specificity (0.0/20 points).
- Strongest contributor
- Procurement Impact
- Limiting factor
- Impact-Scale Specificity